Overview

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-07-24
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Phase:
PHASE2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated